219-OR: Impact Of Inpen Smart Insulin Pen Use on Real-World Glycemic and Insulin Dosing Outcomes in Individuals with Poorly Controlled Diabetes
Robert Alan Vigerskya, Madison Smitha, SNEHA THANASEKARANa, Angela Gaetanoa, GLEN HEUNGYONG IMa, Toni L. Corderoa, Janice MacLeoda
- aNorthridge, CA
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
Background: Smart insulin pens that track the timing and amount of insulin administration, communicate with phone apps that provide bolus calculators and integrate CGM data are emerging as important technology for users of multiple daily injections (MDI) therapy, as they can improve glycemic outcomes and be more cost-effective compared to some standards of care.1,2 Early real-world outcomes of InPen™ smart insulin pen users were assessed in the present study. Methods: Deidentified CGM-derived data from N=1736 individuals before and up to 90 days after starting InPen use between Jan. 2018 to Oct. 2020 were evaluated. Glycemic outcomes including mean sensor glucose (SG), glucose management indicator (GMI), and percentage of time spent between 70-180mg/dL (TIR), >180mg/dL (TAR) and <70mg/dL (TBR) ranges were determined and analyzed (Wilcoxon signed-rank test). Results: Compared to pre-InPen use, individuals (N=423) with suboptimal baseline glycemic control (GMI >8.0%) had increased TIR (+2.3%, 0.6h/day); and reduced GMI (-0.1%), SG (-4.3mg/dL) and TAR (-2.4%); with no change in TBR. Those with poorest glycemic control at baseline (GMI >9.5, N=106) had TIR that improved by +5.0% (1.2h/day), GMI by -0.4%, SG by -14.9mg/dL, and TAR by -5.1% (-1.2h/day), with no change in TBR. From the first month to 90-days post-InPen use, average daily insulin bolus frequency decreased (from 3.7 to 3.6/day and 3.3 to 3.2/day, respectively, for each group) and total rapid acting daily dose of insulin increased (from 26.29 to 27.19 u/day and 27.57 to 29.24 u/day, respectively, for each group). All results were significant at p<0.05. Discussion: These data show that InPen use is associated with improved glycemic control and increased doses of bolus insulin in users with poor glycemic control. 1. Jendle J, Ericsson Å, Gundgaard J, et al. Diabetes Ther. 2020; doi: 10.1007/s13300-020-00980-1. 2. Adolfsson P, Hartvig NV, Kaas A, rt al. Diabetes Technol Ther;2020;22:709-718. Disclosure R. Vigersky: Employee; Self; Medtronic. M. Smith: Employee; Self; Companion Medical, Medtronic. S. Thanasekaran: Employee; Self; Companion Medical, Medtronic. A. Gaetano: Employee; Self; Companion Medical, Medtronic. G. Im: Employee; Self; Companion Medical, Medtronic. T. L. Cordero: Employee; Self; Medtronic. J. Macleod: Employee; Self; Companion Medical, Medtronic.
TL;DRSmart insulin pens that track the timing and amount of insulin administration, communicate with phone apps that provide bolus calculators and integrate CGM data are emerging as important technology for users of multiple daily injections therapy, as they can improve glycemic outcomes and be more cost-effective compared to some standards of care. (Semantic Scholar)